Skip to main content
. 2012 Mar 31;14(3):389–399. doi: 10.1208/s12248-012-9348-3

Fig. 1.

Fig. 1

Schematic of a dual-modality PET/optical construct used to explore the properties of IRDye800CW conjugates by Cohen at al. (4). Left Zr-89 chelated with desferrioxamine B. Right An IRDye800CW moiety. Both linked to lysine side groups on the antibody